Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05154487

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers

Sponsor: GOG Foundation

Conditions Endometroid Endometrial Cancer

Interventions Alpelisib Pill Fulvestrant injection

Updated 9 times since 2022 Last updated: Feb 27, 2026 Started: Sep 11, 2024 Primary completion: May 1, 2028 Completion: Nov 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Endometroid Endometrial Cancer, this trial is ongoing. The trial is conducted by GOG Foundation and has accumulated 9 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2025 — Mar 2026 [monthly]

Recruiting PHASE2
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 4 earlier versions

Jan 2024 — Mar 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2023 — Jan 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2022 — Sep 2023 [monthly]

Not Yet Recruiting PHASE2
Jan 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GOG Foundation
Novartis

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Duarte, United States , Indianapolis, United States , Kettering, United States , Lake Success, United States , Louisville, United States , Madison, United States , Miami Beach, United States , Orlando, United States , Portland, United States and 6 more locations